Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...

A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive ...

The following is a summary of “Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR 1, expanding the eligibility of ...

Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...

Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among ...

Sun Pharmaceutical Industries Ltd has entered into an agreement to acquire US-based immunotherapy and targeted oncology ...

The main function of RAD204 – a single domain monoclonal antibody – is its targeting of PD-L1, a protein which helps control ...

Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.